Life Sciences Women's Health Solutions sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Life Sciences Women's Health Solutions
1.1 - About Life Sciences Women's Health Solutions sector
Companies in the Life Sciences Women's Health Solutions category develop diagnostics, devices, digital platforms, and therapeutics tailored to female health across the lifespan. They address reproductive care, prenatal and maternal monitoring, gynecologic conditions, and menopause management. Their value lies in earlier detection, evidence-based treatment, and improved patient engagement, enabling providers and payers to reduce complications, standardize care pathways, and generate real-world data for clinical and economic decision-making.
Offerings commonly include laboratory-developed tests for HPV and STI screening, noninvasive prenatal testing and carrier screening, and point-of-care assays supported by centralized lab analytics. Many vendors deliver maternal remote patient monitoring integrated with telehealth, fertility tracking apps and wearables tied to IVF workflow tools, and pelvic floor therapy and contraceptive devices. They often complement hardware and assays with clinical decision support, outcomes dashboards, and EHR integration to streamline documentation and care coordination.
Primary customers include health systems and hospitals, OB/GYN practices and fertility centers, and biopharma teams focused on women’s health. Buyers seek outcomes such as earlier diagnosis of high-risk pregnancies, reduced maternal morbidity, higher IVF success rates, lower cost of care through remote monitoring, and improved data quality for regulatory reporting and real-world evidence generation—capabilities that make these vendors relevant strategic buyers in women’s health life sciences.
2. Buyers in the Life Sciences Women's Health Solutions sector
2.1 Top strategic acquirers of Life Sciences Women's Health Solutions companies
Natera
- Description: Provider of genetic testing solutions and end-to-end support services for women’s health, oncology and other specialties, leveraging cell-free DNA and next-generation sequencing. Its NateraCore program offers education, financial access, streamlined ordering, electronic results, and genetic counseling to help clinicians integrate hereditary cancer and other screenings into routine care.
- Key Products:
- NateraCore Services: Comprehensive program delivering patient education, financial access tools, digital and paper ordering, electronic results, and genetic counselor sessions to simplify genetic testing implementation
- Empower Hereditary Cancer Test: Curated gene panels integrated with mammography software, reporting genetic findings with Tyrer-Cuzick score for a complete breast cancer risk view
- NateraConnect Portal: Web platform allowing paper or digital order entry, integration with EHR networks, and electronic results management within clinicians’ systems
- NEVA – Natera Educational Virtual Assistant: Digital screening and interactive results tool that flags increased-risk patients, delivers reports, and guides patients through testing and results understanding.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Life Sciences Women's Health Solutions sector
M&A buyer group 1: FemTech
Advantia Health
- Type: N/A
- Employees: ●●●●●
- Description: Provider of specialized women’s and individual healthcare services, Advantia Health delivers personalized specialty care—including pelvic floor health, hormone therapy, laparoscopic surgery, telehealth, and LGBTQ+ affirmative treatments—through a network of clinics and virtual consultations.
- Key Products:
- Bladder Leakage & Incontinence Care: Provides advanced diagnostics and treatment plans targeting urinary incontinence, leveraging specialized expertise to improve bladder function and patient quality of life
- Laparoscopic Surgery: Delivers minimally invasive surgical interventions for select gynecologic conditions, utilizing small incisions to reduce postoperative pain, expedite recovery, and minimize hospital stays
- LGBTQ+ and Gender Affirming Care: Designs personalized, gender-affirming treatment pathways, hormonal support, and ongoing health monitoring to meet unique needs of LGBTQ+ individuals in an inclusive environment
- Telehealth Visits: Enables virtual consultations and follow-ups through secure digital channels, granting convenient access to specialists regardless of patient location, mobility constraints, or scheduling challenges.
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Life Sciences Women's Health Solutions sector
3.1 - Buyout funds in the Life Sciences Women's Health Solutions sector
2.2 - Strategic buyer groups for Life Sciences Women's Health Solutions sector
4 - Top valuation comps for Life Sciences Women's Health Solutions companies
4.2 - Public trading comparable groups for Life Sciences Women's Health Solutions sector
Valuation benchmark group 1: Molecular Diagnostics and Genomics Tools Companies
Agilent Technologies
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of design, manufacturing, and marketing of measurement instruments primarily for communications, electronics, life sciences, and chemistry sectors.
- Key Products:
- Gas Chromatographs: Instruments for separating chemical compounds into individual components for analysis
- Liquid Chromatographs: Tools for separating, identifying, and quantifying components in a liquid sample
- Mass Spectrometers: Analyzers for identifying chemical structures and determining molecule weights
- Lab Automation Systems: Robots and software for enhancing efficiency in laboratory workflows
- Genomics Solutions: Products for gene sequencing, expression analysis, and mutation detection.